MiR-194, commonly repressed in colorectal cancer, suppresses tumor growth by regulating the MAP4K4/c- Jun/MDM2 signaling pathway

Cell Cycle

Volumn 14, Issue 7, 2015, Pages 1046-1058

  Wang, Bo ^a   Shen, Zhan Long ^a   Gao, Zhi Dong ^a   Zhao, Gang ^b   Wang, Chun You ^b   Yang, Yang ^a   Zhang, Ji Zhun ^a   Yan, Yi Chao ^a   Shen, Chao ^a   Jiang, Ke Wei ^a   Ye, Ying Jiang ^a   Wang, Shan ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Apoptosis; C Jun; Colorectal cancer; MAP4K4; MDM2; MiR 194; Proliferation

Indexed keywords

MICRORNA; MICRORNA 194; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN C JUN; PROTEIN MAP4K4; PROTEIN MDM2; UNCLASSIFIED DRUG; 3' UNTRANSLATED REGION; MAP4K4 PROTEIN, HUMAN; MDM2 PROTEIN, HUMAN; MIRN194 MICRORNA, HUMAN; PROTEIN BINDING; PROTEIN SERINE THREONINE KINASE; SIGNAL PEPTIDE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CANCER STAGING; CANCER SURVIVAL; CANCER TISSUE; CARCINOGENESIS; CELL PROLIFERATION; COLORECTAL CANCER; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE OVEREXPRESSION; GENE REPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; KAPLAN MEIER METHOD; LUCIFERASE ASSAY; MALE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; OVERALL SURVIVAL; PROMOTER REGION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TUMOR DIFFERENTIATION; TUMOR GROWTH; TUMOR VOLUME; 3' UNTRANSLATED REGION; ANIMAL; APOPTOSIS; BAGG ALBINO MOUSE; BINDING SITE; CANCER TRANSPLANTATION; COLORECTAL TUMOR; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MORTALITY; MULTIVARIATE ANALYSIS; NUCLEOTIDE SEQUENCE; NUDE MOUSE; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RNA INTERFERENCE; TUMOR CELL LINE;

3' UNTRANSLATED REGIONS; ANIMALS; APOPTOSIS; BASE SEQUENCE; BINDING SITES; CELL LINE, TUMOR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DOWN-REGULATION; FEMALE; G1 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KAPLAN-MEIER ESTIMATE; MICE, INBRED BALB C; MICE, NUDE; MICRORNAS; MULTIVARIATE ANALYSIS; NEOPLASM TRANSPLANTATION; PROGNOSIS; PROMOTER REGIONS, GENETIC; PROPORTIONAL HAZARDS MODELS; PROTEIN BINDING; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-JUN; PROTO-ONCOGENE PROTEINS C-MDM2; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

EID: 84928125704     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.1080/15384101.2015.1007767     Document Type: Article

References (53)

1. Siegel R, Desantis C, Jemal A. Colorectal cancer statistics, 2014. CA Cancer J Clin 2014; 64:104-17; PMID:24639052; http://dx.doi.org/10.3322/caac.21220
2. Chen DL, Wang ZQ, Zeng ZL, Wu WJ, Zhang DS, Luo HY, Wang F, Qiu MZ, Wang DS, Ren C, et al. Identification of MicroRNA-214 as a negative regulator of colorectal cancer liver metastasis by way of regulation of fibroblast growth factor receptor 1 expression. Hepatology 2014; 60:598-609; PMID:24616020; http://dx.doi.org/10.1002/hep.27118
3. Valeri N, Braconi C, Gasparini P, Murgia C, Lampis A, Paulus-Hock V, Hart JR, Ueno L, Grivennikov SI, Lovat F, et al. MicroRNA-135b promotes cancer progression by acting as a downstream effector of oncogenic pathways in colon cancer. Cancer Cell 2014; 25:469-483; PMID:24735923; http://dx.doi.org/10.1016/j.ccr.2014.03.006
4. Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman N, et al. The consensus coding sequences of human
5. breast and colorectal cancers. Science 2006; 314:268-274; PMID:16959974; http://dx.doi.org/10.1126/science.1133427
6. De Roock W, De Vriendt V, Normanno N, Ciardiello F, Tejpar S. KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol 2011; 12:594-603; PMID:21163703; http://dx.doi.org/10.1016/S1470-2045(10)70209-6
7. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116:281-97; PMID:14744438; http://dx.doi.org/10.1016/S0092-8674(04)00045-5
8. Winter J, Jung S, Keller S, Gregory RI, Diederichs S. Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol 2009; 11:228-234; PMID:19255566; http://dx.doi.org/10.1038/ncb0309-228
9. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, et al. MicroRNA expression profiles classify human cancers. nature 2005; 435:834-838; PMID:15944708; http://dx.doi.org/10.1038/nature03702
10. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nature Reviews Cancer 2006; 6:857-66; PMID:17060945; http://dx.doi.org/10.1038/nrc1997
11. Li Z, Ying X, Chen H, Ye P, Shen Y, Pan W, Zhang L MicroRNA-194 Inhibits the Epithelial-Mesenchymal Transition in Gastric Cancer Cells by Targeting FoxM1. Dig Dis Sci 2014; 59:2145-52;
12. PMID:24748184; http://dx.doi.org/10.1007/s10620-014-3159-6
13. Zhai H, Karaayvaz M, Dong P, Sakuragi N, Ju J. Prognostic significance of miR-194 in endometrial cancer. Biomark Res 2013; 1; PMID:24040515; http://dx.doi.org/10.1186/2050-7771-1-12
14. Khella HW, Bakhet M, Allo G, Jewett MA, Girgis AH, Latif A, Girgis H, Von Both I, Bjarnason GA, Yousef GM. miR-192, miR-194 and miR-215: a convergent microRNA network suppressing tumor progression in renal cell carcinoma. Carcinogenesis 2013; 34:2231-2239;PMID:23715501; http://dx.doi.org/10.1093/carcin/bgt184
15. Wu X, Liu T, Fang O, Leach LJ, Hu X, Luo Z. miR-194 suppresses metastasis of non-small cell lung cancer through regulating expression of BMP1 and p27kip1. Oncogene 2014; 33:1506-14; PMID:23584484; http://dx.doi.org/10.1038/onc.2013.108
16. Le XF, Almeida MI, Mao W, Spizzo R, Rossi S, Nicoloso MS, Zhang S, Wu Y, Calin GA, Bast RC Jr. Modulation of MicroRNA-194 and cell migration by HER2-targeting trastuzumab in breast cancer. PLoS One 2012; 7:e41170; PMID:22829924; http://dx.doi.org/10.1371/journal.pone.0041170
17. Zhang J, Zhao CY, Zhang SH, Yu DH, Chen Y, Liu QH, Shi M, Ni CR, Zhu MH. Upregulation of miR-194 contributes to tumor growth and progression in pancreatic ductal adenocarcinoma. Oncol Rep 2014;31:1157-1164; PMID:24398877
18. Chiang Y, Song Y, Wang Z, Liu Z, Gao P, Liang J, Zhu J, Xing C, Xu H. microRNA-192, -194 and -215 are frequently downregulated in colorectal cancer. Exp Ther Med 2012; 3:560-6; PMID:22969930
19. Wang ZH, Ren LL, Zheng P, Zheng HM, Yu YN, Wang JL, Lin YW, Chen YX, Ge ZZ, Chen XY, et al. MiR-194 as a predictor for adenoma recurrence in patients with advanced colorectal adenoma after polypectomy. Cancer Prev Res (Phila) 2014; 7:607-616; PMID:24691499; http://dx.doi.org/10.1158/1940-6207.CAPR-13-0426
20. Sundaram P, Hultine S, Smith LM, Dews M, Fox JL, Biyashev D, Schelter JM, Huang Q, Cleary MA, Volpert OV, et al. p53-responsive miR-194 inhibits thrombospondin-1 and promotes angiogenesis in colon cancers. Cancer Res 2011; 71:7490-501; PMID:22028325; http://dx.doi.org/10.1158/0008-5472.CAN-11-1124
21. Wright JH, Wang X, Manning G, LaMere BJ, Le P, Zhu S, Khatry D, Flanagan PM, Buckley SD, Whyte DB, et al. The STE20 kinase HGK is broadly expressed in human tumor cells and can modulate cellular transformation, invasion, and adhesion. Mol Cell Biol 2003; 23:2068-82; PMID:12612079; http://dx.doi.org/10.1128/MCB.23.6.2068-2082.2003
22. Rizzardi AE, Rosener NK, Koopmeiners JS, Isaksson VR, Metzger GJ, Forster CL, Marston LO, Tiffany JR, McCarthy JB, Turley EA, et al. Evaluation of protein biomarkers of prostate cancer aggressiveness. BMC Cancer 2014; 14:244; PMID:24708576; http://dx.doi.org/10.1186/1471-2407-14-244
23. Liu AW, Cai J, Zhao XL, Jiang TH, He TF, Fu HQ, Zhu MH, Zhang SH. ShRNA-targeted MAP4K4 inhibits hepatocellular carcinoma growth. Clin Cancer Res 2011; 17:710-720; PMID:21196414; http://dx.doi.org/10.1158/1078-0432.CCR-10-0331
24. Qiu MH, Qian YM, Zhao XL, Wang SM, Feng XJ, Chen XF, Zhang SH. Expression and prognostic significance of MAP4K4 in lung adenocarcinoma. Pathol Res Pract 2012; 208:541-8; PMID:22824148; http://dx.doi.org/10.1016/j.prp.2012.06.001
25. Zhao G, Wang B, Liu Y, Zhang JG, Deng SC, Qin Q, Tian K, Li X, Zhu S, Niu Y, et al. miRNA-141, downregulated in pancreatic cancer, inhibits cell proliferation and invasion by directly targeting MAP4K4. Mol Cancer Ther 2013; 12:2569-80; PMID:24013097; http://dx.doi.org/10.1158/1535-7163.MCT-13-0296
26. Bartel F, Taubert H, Harris LC. Alternative and aberrant splicing of MDM2 mRNA in human cancer. Cancer Cell 2002; 2:9-15; PMID:12150820; http://dx.doi.org/10.1016/S1535-6108(02)00091-0
27. Wade M, Li YC, Wahl GM. MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer 2013; 13:83-96; PMID:23303139; http://dx.doi.org/10.1038/nrc3430
28. Huang M, Zhang H, Liu T, Tian D, Gu L, Zhou M. Triptolide inhibits MDM2 and induces apoptosis in acute lymphoblastic leukemia cells through a p53-independent pathway. Mol Cancer Ther 2013; 12:184-94; PMID:23243057; http://dx.doi.org/10.1158/1535-7163.MCT-12-0425
29. Jung CH, Kim J, Park JK, Hwang SG, Moon SK, Kim WJ, Um HD. Mdm2 increases cellular invasiveness by binding to and stabilizing the Slug mRNA. Cancer Lett 2013; 335:270-7; PMID:23438693; http://dx.doi.org/10.1016/j.canlet.2013.02.035
30. Kaindl U, Morak M, Portsmouth C, Mecklenbrauker A, Kauer M, Zeginigg M, Attarbaschi A, Haas OA, Panzer-Grümayer R. Blocking ETV6/RUNX1-induced MDM2 overexpression by Nutlin-3 reactivates p53 signaling in childhood leukemia. Leukemia 2014; 28: 600-608; PMID:24240203; http://dx.doi.org/10.1038/leu.2013.345
31. Carvajal D, Tovar C, Yang H, Vu BT, Heimbrook DC, Vassilev LT. Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors. Cancer Res 2005; 65:1918-1924; PMID:15753391; http://dx.doi.org/10.1158/0008-5472.CAN-04-3576
32. Chaar I, Amara S, Khiari M, Ounissi D, Dhraif M, Ben HAE, Gharbi L, Mzabi S, Bouraoui S. Relationship between MDM2 and p53 alterations in colorectal cancer and their involvement and prognostic value in the Tunisian population. Appl mmunohistochem Mol Morphol 2013; 21:228-236; PMID:22914606
33. Tesz GJ, Guilherme A, Guntur KV, Hubbard AC, Tang X, Chawla A, Czech MP. Tumor necrosis factor alpha (TNFalpha) stimulates Map4k4 expression through TNFalpha receptor 1 signaling to c-Jun and activating transcription factor 2. J Biol Chem 2007; 282:19302-19312; PMID:17500068; http://dx.doi.org/10.1074/jbc.M700665200
34. Shimokawa N, Qiu CH, Seki T, Dikic I, Koibuchi N. Phosphorylation of JNK is involved in regulation of H (+)-induced c-Jun expression. Cell Signal 2004; 16:723-729; PMID:15093613; http://dx.doi.org/10.1016/j.cellsig.2003.11.005
35. Toh WH, Siddique MM, Boominathan L, Lin KW, Sabapathy K. c-Jun regulates the stability and activity of the p53 homologue, p73. J Biol Chem 2004; 279:44713-44722; PMID:15302867; http://dx.doi.org/10.1074/jbc.M407672200
36. Xu YM, Zhu F, Cho YY, Carper A, Peng C, Zheng D, Yao K, Lau AT, Zykova TA, Kim HG, et al. Extracellular signal-regulated kinase 8-mediated c-Jun phosphorylation increases tumorigenesis of human colon cancer. Cancer Res 2010; 70:3218-3227; PMID:20395206; http://dx.doi.org/10.1158/0008-5472.CAN-09-4306
37. Chao CH, Chang CC,Wu MJ, Ko HW,Wang D,Hung MC, Yang JY, Chang CJ. MicroRNA-205 signaling regulates mammary stem cell fate and tumorigenesis. J Clin Invest 2014; 124:3093-3106; PMID:24911147; http://dx.doi.org/10.1172/JCI73351
38. Han TS, Hur K, AUID Oho, Xu G, Choi B, Okugawa Y, Toiyama Y, Oshima H, Oshima M, Lee HJ, et al. MicroRNA-29c mediates initiation of gastric carcinogenesis by directly targeting ITGB1. Gut 2014; 64:203-214; PMID:24870620; http://dx.doi.org/10.1136/gutjnl-2013-306640
39. Liu S, Sun X, Wang M, Hou Y, Zhan Y, Jiang Y, Liu S, Sun X, Wang M, Hou Y, et al. A microRNA 221-and222-Mediated Feedback Loop, via PDLIM2, Maintains Constitutive Activation of NFkappaB and STAT3 in Colorectal Cancer Cells. Gastroenterology 2014; 147:847-859; PMID:24931456; http://dx.doi.org/10.1053/j.gastro.2014.06.006
40. Tan YG, Zhang YF, Guo CJ, Yang M, Chen MY. Screening of differentially expressed microRNA in ulcerative colitis related colorectal cancer. Asian Pac J Trop Med 2013; 6:972-6; PMID:24144030; http://dx.doi.org/10.1016/S1995-7645(13)60174-1
41. Meng Z, Fu X, Chen X, Zeng S, Tian Y, Jove R, Xu R, HuangW. miR-194 is a marker of hepatic epithelial cells and suppresses metastasis of liver cancer cells in mice. Hepatology 2010; 52:2148-57; PMID:20979124; http://dx.doi.org/10.1002/hep.23915
42. Selth LA, Townley SL, Bert AG, Stricker PD, Sutherland PD, Horvath LG, Goodall GJ, Butler LM, Tilley WD. Circulating microRNAs predict biochemical recurrence in prostate cancer patients. Br J Cancer 2013; 109:641-50; PMID:23846169; http://dx.doi.org/10.1038/bjc.2013.369
43. Wright JH, Wang X, Manning G, LaMere BJ, Le P, Zhu S, Khatry D, Flanagan PM, Buckley SD, Whyte DB, et al. The STE20 kinase HGK is broadly expressed in human tumor cells and can modulate cellular transformation, invasion, and adhesion. Mol Cell Biol 2003; 23:2068-82; PMID:12612079; http://dx.doi.org/10.1128/MCB.23.6.2068-2082.2003
44. Qiu MH, Qian YM, Zhao XL, Wang SM, Feng XJ, Chen XF, Zhang SH. Expression and prognostic significance of MAP4K4 in lung adenocarcinoma. Pathol Res Pract 2012; 208:541-8; PMID:22824148; http://dx.doi.org/10.1016/j.prp.2012.06.001
45. Ye Y, Li X, Yang J, Miao S, Wang S, Chen Y, Xia X, Wu X, Zhang J, Zhou Y, et al. MDM2 is a useful prognostic biomarker for resectable gastric cancer. Cancer Sci 2013; 104:590-8 ;PMID:23347235; http://dx.doi.org/10.1111/cas.12111
46. Yu Q, Li Y, Mu K, Li Z, Meng Q, Wu X, Wang Y, Li L. Amplification of Mdmx and overexpression of MDM2 contribute to mammary carcinogenesis by substituting for p53 mutations. Diagn Pathol 2014; 9:71; PMID:24667108; http://dx.doi.org/10.1186/1746-1596-9-71
47. Watanabe T, Takeda A, Mise K, Okuno T, Suzuki T, Minami N, Imai H. Stage-specific expression of micro- RNAs during Xenopus development. FEBS Lett 2005; 579:318-24; PMID:15642338; http://dx.doi.org/10.1016/j.febslet.2004.11.067
48. Thomson JM, Parker J, Perou CM, Hammond SM. A custom microarray platform for analysis of microRNA gene expression. Nat Methods 2004; 1:47-53; PMID:15782152; http://dx.doi.org/10.1038/nmeth704
49. Collins CS, Hong J, Sapinoso L, Zhou Y, Liu Z, Micklash K, Schultz PG, Hampton GM. A small interfering RNA screen for modulators of tumor cell motility identifies MAP4K4 as a promigratory kinase. Proc Natl Acad Sci U S A 2006; 103:3775-80; PMID:16537454; http://dx.doi.org/10.1073/pnas.0600040103
50. Hwang JH, Voortman J, Giovannetti E, Steinberg SM, Leon LG, Kim YT, Funel N, Park JK, Kim MA, Kang GH, et al. Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer. PLoS One 2010; 5:e10630; PMID:20498843; http://dx.doi.org/10.1371/journal.pone.0010630
51. Lee BL, Lee HS, Jung J, Cho SJ, Chung HY, Kim WH, Jin YW, Kim CS, Nam SY. Nuclear factor-kB activation correlates with better prognosis and Akt activation
52. in human gastric cancer. Clinical cancer research 2005; 11:2518-25; PMID:15814628; http://dx.doi.org/10.1158/1078-0432.CCR-04-1282
53. Li L, Wang L, Song P, Geng X, Liang X, Zhou M, Wang Y, Chen C, Jia J, Zeng J. Critical role of histonedemethylase RBP2 in human gastric cancer angiogenesis. Mol Cancer 2014; 13:81; PMID:24716659; http://dx.doi.org/10.1186/1476-4598-13-81